Shuang Yang1, Ya-Chen Tina Shih2, Jinhai Huo3, Hiren J Mehta4, Yonghui Wu1, Ramzi G Salloum1, Michelle Alvarado5, Dongyu Zhang6, Dejana Braithwaite6, Yi Guo7, Jiang Bian8. 1. Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, United States. 2. Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, TX, United States. 3. Bristol-Myers Squibb, Princeton Pike, NJ, United States. 4. Division of Pulmonary, Critical Care, and Sleep Medicine, College of Medicine, University of Florida, Gainesville, FL, United States. 5. Department of Industrial and Systems Engineering, University of Florida, Gainesville, FL, United States. 6. Cancer Control and Population Sciences Program, University of Florida, Gainesville, FL, United States. 7. Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, United States. Electronic address: yiguo@ufl.edu. 8. Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, FL, United States. Electronic address: bianjiang@ufl.edu.
Abstract
INTRODUCTION: Although the National Lung Screening Trial (NLST) has proven low-dose computed tomography (LDCT) is effective for lung cancer screening, little is known about complication rates from invasive diagnostic procedures (IDPs) after LDCT in real-world settings. In this study, we used the real-world data from a large clinical research network to estimate the complication rates associated with IDPs after LDCT. METHODS: Using 2014-2021 electronic health records and claims data from the OneFlorida clinical research network, we identified case individuals who underwent an IDP (i.e., cytology or needle biopsy, bronchoscopy, thoracic surgery, and other surgery) within 12 months of their first LDCT. We matched each case with one control individual who underwent an LDCT but without any IDPs. We calculated 3-month incremental complication rates as the difference in the complication rate between the case and control groups by IDP and complication severity. RESULTS: Among 7,041 individuals who underwent an LDCT, 301 (4.3%) subsequently had an IDP within 12 months following the LDCT. The overall 3-month incremental complication rate was 16.6% (95% confidence interval [CI]: 9.9% - 23.1%), higher than that reported in the NLST (9.4%). The overall incremental complication rate was 5.6% (95% CI: 1.9% - 9.6%) for major, 8.6% (95% CI: 3.1% - 14.1%) for intermediate, and 13.2% (95% CI: 8.1% - 18.5%) for minor complications. CONCLUSIONS: It is important to ensure adherence to clinical guidelines for nodule management and downstream work-up to minimize potential harms from screening.
INTRODUCTION: Although the National Lung Screening Trial (NLST) has proven low-dose computed tomography (LDCT) is effective for lung cancer screening, little is known about complication rates from invasive diagnostic procedures (IDPs) after LDCT in real-world settings. In this study, we used the real-world data from a large clinical research network to estimate the complication rates associated with IDPs after LDCT. METHODS: Using 2014-2021 electronic health records and claims data from the OneFlorida clinical research network, we identified case individuals who underwent an IDP (i.e., cytology or needle biopsy, bronchoscopy, thoracic surgery, and other surgery) within 12 months of their first LDCT. We matched each case with one control individual who underwent an LDCT but without any IDPs. We calculated 3-month incremental complication rates as the difference in the complication rate between the case and control groups by IDP and complication severity. RESULTS: Among 7,041 individuals who underwent an LDCT, 301 (4.3%) subsequently had an IDP within 12 months following the LDCT. The overall 3-month incremental complication rate was 16.6% (95% confidence interval [CI]: 9.9% - 23.1%), higher than that reported in the NLST (9.4%). The overall incremental complication rate was 5.6% (95% CI: 1.9% - 9.6%) for major, 8.6% (95% CI: 3.1% - 14.1%) for intermediate, and 13.2% (95% CI: 8.1% - 18.5%) for minor complications. CONCLUSIONS: It is important to ensure adherence to clinical guidelines for nodule management and downstream work-up to minimize potential harms from screening.
Authors: Douglas E Wood; George A Eapen; David S Ettinger; Lifang Hou; David Jackman; Ella Kazerooni; Donald Klippenstein; Rudy P Lackner; Lorriana Leard; Ann N C Leung; Pierre P Massion; Bryan F Meyers; Reginald F Munden; Gregory A Otterson; Kimberly Peairs; Sudhakar Pipavath; Christie Pratt-Pozo; Chakravarthy Reddy; Mary E Reid; Arnold J Rotter; Matthew B Schabath; Lecia V Sequist; Betty C Tong; William D Travis; Michael Unger; Stephen C Yang Journal: J Natl Compr Canc Netw Date: 2012-02 Impact factor: 11.908
Authors: Denise R Aberle; Christine D Berg; William C Black; Timothy R Church; Richard M Fagerstrom; Barbara Galen; Ilana F Gareen; Constantine Gatsonis; Jonathan Goldin; John K Gohagan; Bruce Hillman; Carl Jaffe; Barnett S Kramer; David Lynch; Pamela M Marcus; Mitchell Schnall; Daniel C Sullivan; Dorothy Sullivan; Carl J Zylak Journal: Radiology Date: 2010-11-02 Impact factor: 11.105
Authors: Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks Journal: N Engl J Med Date: 2011-06-29 Impact factor: 91.245
Authors: Alex H Krist; Karina W Davidson; Carol M Mangione; Michael J Barry; Michael Cabana; Aaron B Caughey; Esa M Davis; Katrina E Donahue; Chyke A Doubeni; Martha Kubik; C Seth Landefeld; Li Li; Gbenga Ogedegbe; Douglas K Owens; Lori Pbert; Michael Silverstein; James Stevermer; Chien-Wen Tseng; John B Wong Journal: JAMA Date: 2021-03-09 Impact factor: 56.272
Authors: Elizabeth Shenkman; Myra Hurt; William Hogan; Olveen Carrasquillo; Steven Smith; Andrew Brickman; David Nelson Journal: Acad Med Date: 2018-03 Impact factor: 6.893
Authors: Dejana Braithwaite; Shama D Karanth; Christopher G Slatore; Dongyu Zhang; Jiang Bian; Rafael Meza; Jihyoun Jeon; Martin Tammemagi; Mattthew Schabath; Meghann Wheeler; Yi Guo; Bruno Hochhegger; Frederic J Kaye; Gerard A Silvestri; Michael K Gould Journal: BMJ Open Date: 2022-06-22 Impact factor: 3.006